Nociceptin Receptor Antagonist
Phase 2Small molecule
Nociceptin Receptor Antagonist is one of 6 small molecule programs targeting Neuroimaging. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Neuroimaging
#DrugCompanyPhaseTrials
1Psilocybin
COMPASS PathwaysPhase 2
Ketalar
AAultman Health Foundation
Phase 1
Anerem
AAcacia Pharma Ltd
Phase 1
Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Nociceptin Receptor Antagonist
MMclean Hospital
Phase 2
Mavoglurant
YYale University
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMclean Hospital